RxDoctor Payments Data

Nadia Amin, MD

Internal Medicine · Cortlandt Manor, NYNPI 1962693937

Payments from drug & device makers

$8,390in general payments, 2019–2025

Across 447 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$913
  • Pfizer$604
  • Lilly USA, LLC$583
  • Boehringer Ingelheim$404
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,376100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,390 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$66,440
Medicare patients
198
Services billed
844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$56,696
OzempicSemaglutide26$33,648
VraylarCariprazine Hcl15$31,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,794
FarxigaDapagliflozin Propanediol14$16,632
RybelsusSemaglutide11$11,234
Icosapent Ethyl23$5,580
Rosuvastatin Calcium135$4,235
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,595
Atorvastatin Calcium174$1,945
Metoprolol Succinate71$1,678
Diclofenac Sodium21$1,610
Valsartan38$1,535
Azelastine Hcl38$1,358
Levothyroxine Sodium106$1,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$583$56,69640 claims
Novo NordiskOzempic, Rybelsus$1,533$44,88237 claims
AbbVieVraylar, Synthroid$1,763$32,93028 claims
GSKTrelegy Ellipta$316$17,79419 claims
AstraZenecaFarxiga$913$16,63214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Cortlandt Manor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →